gacyclidine
Small moleculeexperimental
Gacyclidine is a psychoactive drug which acts as a dissociative via functioning as a non-competitive NMDA receptor antagonist. It is closely related to phencyclidine (PCP), and specifically, is a derivative of tenocyclidine (TCP). — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 4, 2019 (NCT03918109)
Timeline
Indications
Studied for
Mechanism of action
- Glutamate NMDA receptorANTAGONIST
Glutamate NMDA receptor antagonist
- Glutamate receptor ionotropic, NMDA 2A (Grin2a) ↗
- Glutamate receptor ionotropic, NMDA 3B (Grin3b) ↗
- Glutamate receptor ionotropic, NMDA 2D (Grin2d) ↗
- Glutamate receptor ionotropic, NMDA 1 (Grin1) ↗
- Glutamate receptor ionotropic, NMDA 2B (Grin2b) ↗
- Glutamate receptor ionotropic, NMDA 2C (Grin2c) ↗
- Glutamate receptor ionotropic, NMDA3A (Grin3a) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CC1CCCCC1(c1cccs1)N1CCCCC1- Mol. weight
- 263.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGacyclidine ↗
- ChEMBLCHEMBL3989791 ↗
Also known as
- gacyclidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04829214 | Phase 2 | Mar 22, 2021 | Otonomy, Inc. |
| NCT03918109 | Phase 1/Phase 2 (Phase 2) | Apr 4, 2019 | Otonomy, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otonomy, Inc. | For profit | 2 | 2 | 1 | 2019 |
1 organizations
Page 1 / 1